Position in CADL
as of Jun 30, 2026
· filed Aug 11, 2026
Position Value
$1,472,672
+$1,016,198 QoQ
Shares Held
142,978
+53.5% QoQ
Ownership
0.187%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#27
of 138 holders
Holding Since
Mar 2025
6 quarters on record
Voting authority
Sole 100%
Shared 0%
None 0%
Common Shares in CADL Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Nuveen, LLC holds $4,913,712,081 across 286 Biotechnology names. CADL ranks #175 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | REGN |
Regeneron Pharmaceuticals, Inc.
|
2,019,974 | $1,259,534,587 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
1,081,685 | $537,305,388 | |
| 3 | EXEL |
Exelixis, Inc.
|
3,276,984 | $178,300,697 | |
| 4 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
315,630 | $95,014,096 | |
| 5 | TGTX |
Tg Therapeutics, Inc.
|
1,625,876 | $89,325,625 | |
| 6 | RVMD |
Revolution Medicines, Inc.
|
475,231 | $89,001,259 | |
| 7 | JAZZ |
Jazz Pharmaceuticals plc
|
365,405 | $88,051,641 | |
| 8 | ROIV |
Roivant Sciences Ltd.
|
1,970,504 | $69,736,134 |
All Filings in CADL
Export CSV
6 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $1,472,672 | 142,978 | Shares | Defined | 2026-08-11 | |
| 2026-03-31 | $456,474 | 93,158 | Shares | Defined | 2026-04-30 | |
| 2025-12-31 | $522,523 | 92,482 | Shares | Defined | 2026-02-12 | |
| 2025-09-30 | $1,069,276 | 209,662 | Shares | Defined | 2025-11-12 | |
| 2025-06-30 | $467,958 | 92,482 | Shares | Defined | 2025-08-12 | |
| 2025-03-31 | $441,519 | 78,145 | Shares | Defined | 2025-05-12 | |
| No filing history on record for this holder in this stock. | ||||||